Celgene Reports Results of CC-486 in P-III QUAZAR AML-001 Study as Maintenance Therapy for Acute Myeloid Leukemia

Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for Multiple Myeloma


  • The P-III QUAZAR AML-001 study involves assessing of CC-486 (300mg) as maintenance therapy vs PBO + SoC in 472 patients in a ratio (1:1) with AML who achieved first CR with incomplete blood count recovery (CRi) with induction chemotherapy (with/out consolidation)
  • The P-III QUAZAR AML-001 study resulted in meeting its 1EPs & 2EPs i.e, improvement in OS & RFS, safety, tolerability, healthcare resource utilization and patient-reported outcomes per the FACIT-Fatigue Scale and EQ-5D questionnaire respectively
  • CC-486 is an analog of cytidine nucleoside, incorporated into DNA & RNA act by causing DNA hypomethylation and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow with its anticipated regulatory submissions in H1’20

Click here to­ read full press release/ article | Ref: Celgene | Image: Bio Online